Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
The agreement provides for acquisition of 13,50,000 equity shares of Rs. 100 each constituting 50% of the total equity share capital
Both products are broad-spectrum, foliar insecticides used across wide range of crops
The product will be manufactured at Lupin's facility in Nagpur, India.
The inspection concluded with no observation (FDA-483) issued.
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
The inspection of the facility was conducted from August 16-19, 2022.
This new initiative will cater to the increasing number of patients in Karnataka in need of heart and lung Failure management and transplant
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Subscribe To Our Newsletter & Stay Updated
